Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Verzenio

- PMLiVE

Amgen’s Imdelltra granted FDA accelerated approval to treat small cell lung cancer

More than 234,000 new cases of lung cancer are expected to be diagnosed in the US this year

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin efsitora in type 2 diabetes

It is hoped that a once-weekly treatment option could lead to improved adherence

- PMLiVE

Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A

The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies

- PMLiVE

Study reveals new breast cancer genes found in women of African ancestry

More than 240,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

Bristol Myers Squibb’s Breyanzi granted FDA accelerated approval for follicular lymphoma

The disease accounts for up to 30% of all non-Hodgkin lymphoma cases

Biogen Idec building

Biogen and Eisai announce rolling FDA submission for injectable version of Alzheimer’s drug

The Leqembi SC autoinjector could reduce the need for hospital visits and nursing care compared to IV administration

- PMLiVE

Roche announces FDA approval of self-collection solution for HPV screening

More than 13,000 people are diagnosed with cervical cancer every year in the US

- PMLiVE

NICE recommends three tumour profiling tests for early breast cancer patients

Breast cancer is the most common cancer in the UK, affecting more than 55,000 people every year

- PMLiVE

New immune cell discovery could lead to personalised breast cancer treatments

The study revealed the key features of immune cells in helping the body’s immune system fight cancer

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in phase 3 breast cancer study

More than two million cases of breast cancer were diagnosed globally in 2022

- PMLiVE

UK study reveals significantly higher risk of second cancers among breast cancer survivors

Breast cancer is currently the most commonly diagnosed cancer in the UK, affecting around 56,000 people annually

- PMLiVE

Pfizer/Genmab’s Tivdak granted full FDA approval for recurrent or metastatic cervical cancer

It is estimated that more than 13,960 new cases of invasive cervical cancer were diagnosed in the US last year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links